Inhibition of the adrenomedullin/nitric oxide signaling pathway in early diabetic retinopathy

Journal of Ocular Biology, Diseases, and Informatics

Volumn 4, Issue 1-2, 2011, Pages 70-82

  Blom, Jan J ^a   Giove, Thomas J ^a   Favazza, Tara L ^b   Akula, James D ^b,c   Eldred, William D ^a  

^a Boston University   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adrenomedullin; Diabetic retinopathy; Nitric oxide; PKC ; Ruboxistaurin

Indexed keywords

ADRENOMEDULLIN; GLUCOSE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PROTEIN KINASE C; RUBOXISTAURIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; MALE; MOUSE; NONHUMAN; OSCILLATORY POTENTIAL; PRIORITY JOURNAL; RETINA BIPOLAR GANGLION CELL; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES;

MUS;

EID: 84863984452     PISSN: 19368437     EISSN: 19368445     Source Type: Journal    
DOI: 10.1007/s12177-011-9072-8     Document Type: Article

References (102)

1. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol. 2003;136:122-35. (Pubitemid 36794505)
2. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, Norbury CC, Quinn PG, Sandirasegarane L, Simpson IA. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55:2401-11. (Pubitemid 44871140)
3. Lieth E, Gardner TW, Barber AJ, Antonetti DA. Retinal neurodegeneration: early pathology in diabetes. Clin Experiment Ophthalmol. 2000;28:3-8. (Pubitemid 30433242)
4. Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:283-90. (Pubitemid 36351495)
5. Di Leo MA, Caputo S, Falsini B, Porciatti V, Greco AV, Ghirlanda G. Presence and further development of retinal dysfunction after 3-year follow up in IDDM patients without angiographically documented vasculopathy. Diabetologia. 1994;37:911-6. (Pubitemid 24288031)
6. Parisi V, Uccioli L. Visual electrophysiological responses in persons with type 1 diabetes. Diabetes Metab Res Rev. 2001;17:12-8.
7. Li Q, Zemel E, Miller B, Perlman I. Early retinal damage in experimental diabetes: electroretinographical and morphological observations. Exp Eye Res. 2002;74:615-25. (Pubitemid 34757017)
8. Engerman RL, Kern TS. Retinopathy in animal models of diabetes. Diabetes Metab Rev. 1995;11:109-20.
9. Daley ML, Watzke RC, Riddle MC. Early loss of blue-sensitive color vision in patients with type I diabetes. Diabetes Care. 1987;10:777-81. (Pubitemid 18049836)
10. Roy MS, Gunkel RD, Podgor MJ. Color vision defects in early diabetic retinopathy. Arch Ophthalmol. 1986;104:225-8. (Pubitemid 16119619)
11. Sokol S, Moskowitz A, Skarf B, Evans R, Molitch M, Senior B. Contrast sensitivity in diabetics with and without background retinopathy. Arch Ophthalmol. 1985;103:51-4. (Pubitemid 15152624)
12. Lieth E, Barber AJ, Xu B, Dice C, Ratz MJ, Tanase D, Strother JM. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes. 1998;47:815-20. (Pubitemid 28201813)
13. Martin PM, Roon P, Van Ells TK, Ganapathy V, Smith SB. Death of retinal neurons in streptozotocin-induced diabetic mice. Invest Ophthalmol Vis Sci. 2004;45:3330-6. (Pubitemid 39121873)
14. VanGuilder HD, Brucklacher RM, Patel K, Ellis RW, Freeman WM, Barber AJ. Diabetes downregulates presynaptic proteins and reduces basal synapsin I phosphorylation in rat retina. Eur J Neurosci. 2008;28:1-11.
15. Kern TS, Miller CM, Du Y, Zheng L, Mohr S, Ball SL, Kim M, Jamison JA, Bingaman DP. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes. 2007;56:373-9.
16. Eldred WD. Nitric oxide in the retina. Functional neuroanatomy of the nitric oxide system. 2000. 111-145.
17. Yilmaz G, Esser P, Kociok N, Aydin P, Heimann K. Elevated vitreous nitric oxide levels in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2000;130:87-90.
18. Hattenbach LO, Allers A, Klais C, Koch F, Hecker M. L-Argininenitric oxide pathway-related metabolites in the aqueous humor of diabetic patients. Invest Ophthalmol Vis Sci. 2000;41:213-7. (Pubitemid 30036570)
19. Blute TA, Mayer B, Eldred WD. Immunocytochemical and histochemical localization of nitric oxide synthase in the turtle retina. Vis Neurosci. 1997;14:717-29. (Pubitemid 27416002)
20. Eldred WD, Blute TA. Imaging of nitric oxide in the retina. Vision Res. 2005;45:3469-86. (Pubitemid 41737375)
21. Giove TJ, Deshpande MM, Eldred WD. Identification of alternate transcripts of neuronal nitric oxide synthase in the mouse retina. J Neurosci Res. 2009;87:3134-42.
22. Giove TJ, Deshpande MM, Gagen CS, Eldred WD. Increased neuronal nitric oxide synthase activity in retinal neurons in early diabetic retinopathy. Mol Vis. 2009;15:2249-58.
23. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993;192:553-60. (Pubitemid 23227359)
24. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000;21:138-67. (Pubitemid 32275593)
25. Hay DL, Conner AC, Howitt SG, Smith DM, Poyner DR. The pharmacology of adrenomedullin receptors and their relationship to CGRP receptors. J Mol Neurosci. 2004;22:105-13. (Pubitemid 41359020)
26. Xu Y, Krukoff TL. Adrenomedullin stimulates nitric oxide release from SK-N-SH human neuroblastoma cells by modulating intracellular calcium mobilization. Endocrinology. 2005;146:2295-305. (Pubitemid 40577517)
27. Szokodi I, Kinnunen P, Tavi P, Weckstrom M, Toth M, Ruskoaho H. Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation. 1998;97:1062-70.
28. Huang W, Wang L, Yuan M, Ma J, Hui Y. Adrenomedullin affects two signal transduction pathways and themigration in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2004;45:1507-13. (Pubitemid 38859332)
29. Xu Y, Krukoff TL. Adrenomedullin stimulates nitric oxide production from primary rat hypothalamic neurons: roles of calcium and phosphatases. Mol Pharmacol. 2007;72:112-20. (Pubitemid 46998530)
30. Ito S, Fujisawa K, Sakamoto T, Ishibashi T. Elevated adrenomedullin in the vitreous of patients with diabetic retinopathy. Ophthalmologica. 2003;217:53-7. (Pubitemid 36173456)
31. Er H, Doganay S, Ozerol E, Yurekli M. Adrenomedullin and leptin levels in diabetic retinopathy and retinal diseases. Ophthalmologica. 2005;219:107-11. (Pubitemid 40529288)
32. Udono T, Takahashi K, Takano S, Shibahara S, Tamai M. Elevated adrenomedullin in the vitreous of patients with proliferative vitreoretinopathy. Am J Ophthalmol. 1999;128:765-7. (Pubitemid 30001778)
33. Caliumi C, Balducci S, Petramala L, Cotesta D, Zinnamosca L, Cianci R, Di Donato D, Vingolo EM, Fallucca F, Letizia C. Plasma levels of adrenomedullin, a vasoactive peptide, in type 2 diabetic patients with and without retinopathy. Minerva Endocrinol. 2007;32:73-8.
34. Martinez A, Elsasser TH, Bhathena SJ, Pio R, Buchanan TA, Macri CJ, Cuttitta F. Is adrenomedullin a causal agent in some cases of type 2 diabetes? Peptides. 1999;20:1471-8. (Pubitemid 30069893)
35. Garcia-Unzueta MT, Montalban C, Pesquera C, Berrazueta JR, Amado JA. Plasma adrenomedullin levels in type 1 diabetes. Relationship with clinical parameters. Diabetes Care. 1998;21:999-1003. (Pubitemid 28488795)
36. Taniguchi T, Kawase K, Gu ZB, Kimura M, Okano Y, Kawakami H, Tsuji A, Kitazawa Y. Ocular effects of adrenomedullin. Exp Eye Res. 1999;69:467-74.
37. Clementi G, Floriddia ML, Prato A, Marino A, Drago F. Adrenomedullin and ocular inflammation in the rabbit. Eur J Pharmacol. 2000;400:321-6. (Pubitemid 30438743)
38. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002;288:2579-88. (Pubitemid 35386893)
39. Shore AC. The microvasculature in type 1 diabetes. Semin Vasc Med. 2002;2:9-20.
40. Xu X, Zhu Q, Xia X, Zhang S, Gu Q, Luo D. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr Eye Res. 2004;28:251-6. (Pubitemid 38491318)
41. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci. 1998;39:171-9. (Pubitemid 28040476)
42. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LE, King GL. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46:1473-80. (Pubitemid 27369086)
43. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci. 2006;47:86-92. (Pubitemid 46780799)
44. Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690-6. (Pubitemid 37025424)
45. Suzuma I, Suzuma K, Ueki K, Hata Y, Feener EP, King GL, Aiello LP. Stretch-induced retinal vascular endothelial growth factor expression is mediated by phosphatidylinositol 3-kinase and protein kinase C (PKC)-zeta but not by stretch-induced ERK1/2, Akt, Ras, or classical/novel PKC pathways. J Biol Chem. 2002;277:1047-57. (Pubitemid 34968850)
46. Hayashi M, Shimosawa T, Fujita T. Hyperglycemia increases vascular adrenomedullin expression. Biochem Biophys Res Commun. 1999;258:453-6. (Pubitemid 29287072)
47. Abbracchio MP, Cattabeni F, Di Giulio AM, Finco C, Paoletti AM, Tenconi B, Gorio A. Early alterations of Gi/Go protein-dependent transductional processes in the retina of diabetic animals. J Neurosci Res. 1991;29:196-200.
48. Ishimitsu T, Kojima M, Kangawa K, Hino J,Matsuoka H, Kitamura K, Eto T, Matsuo H. Genomic structure of human adrenomedullin gene. Biochem Biophys Res Commun. 1994;203:631-9. (Pubitemid 24281141)
49. Tsuruda T, Kato J, Kitamura K, Mishima K, Imamura T, Koiwaya Y, Kangawa K, Eto T. Roles of protein kinase C and Ca2+-dependent signaling in angiotensin II-induced adrenomedullin production in rat cardiac myocytes. J Hypertens. 2001;19:757-63. (Pubitemid 32289556)
50. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science. 1996;272:728-31. (Pubitemid 26000279)
51. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A,Ways DK, King GL, Kikkawa R. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 2000;14:439-47. (Pubitemid 30143162)
52. Cotter MA, Jack AM, Cameron NE. Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci (Lond). 2002;103:311-21. (Pubitemid 35007223)
53. Kelly DJ, Zhang Y, Hepper C, Gow RM, Jaworski K, Kemp BE, Wilkinson-Berka JL, Gilbert RE. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes. 2003;52:512-8. (Pubitemid 36173211)
54. Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology. 2006;113:2221-30.
55. Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, DavisMD,Wolka AM, ShahriN,Milton RC. Oral protein kinase C beta inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes)with diabetic retinopathy in the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study and the Protein kinase C beta Inhibitor-Diabetic Retinopathy Study 2. Retina 2011.
56. Sheetz MJ, Aiello LP, Shahri N, Davis MD, Kles KA, Danis RP. Effect of ruboxistaurin (RBX) on visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2). Retina. 2011;31:1053-9.
57. Davis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X, Girach A, Jimenez MC, Vignati L. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci. 2009;50:1-4.
58. Barbuch RJ, Campanale K, Hadden CE, Zmijewski M, Yi P, O'Bannon DD, Burkey JL, Kulanthaivel P. In vivo metabolism of [14C]ruboxistaurin in dogs, mice, and rats following oral administration and the structure determination of its metabolites by liquid chromatography/mass spectrometry and NMR spectroscopy. Drug Metab Dispos. 2006;34:213-24. (Pubitemid 43145023)
59. Pong WW, Stouracova R, Frank N, Kraus JP, Eldred WD. Comparative localization of cystathionine beta-synthase and cystathionine gamma-lyase in retina: differences between amphibians and mammals. J Comp Neurol. 2007;505:158-65. (Pubitemid 350013039)
60. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods. 2001;25:402-8. (Pubitemid 34164012)
61. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald III JH, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, BaevskyM, BallasLM, Hall SE,Winneroski LL, FaulMM. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro- 4,9:16, 21-dimetheno-1H, 13H-dibenzo[e, k]pyrrolo[3,4-h][1,4,13] oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem. 1996;39:2664-71.
62. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide. 2001;5:62-71. (Pubitemid 34146173)
63. Akula JD, Mocko JA, Benador IY, Hansen RM, Favazza TL, Vyhovsky TC, Fulton AB. The neurovascular relation in oxygeninduced retinopathy. Mol Vis. 2008;14:2499-508.
64. Akula JD, Hansen RM, Tzekov R, Favazza TL, Vyhovsky TC, Benador IY, Mocko JA, McGee D, Kubota R, Fulton AB. Visual cycle modulation in neurovascular retinopathy. Exp Eye Res. 2010;91:153-61.
65. Hood DC, Birch DG. A computational model of the amplitude and implicit time of the b-wave of the human ERG. Vis Neurosci. 1992;8:107-26.
66. Lamb TD, Pugh Jr EN. A quantitative account of the activation steps involved in phototransduction in amphibian photoreceptors. J Physiol. 1992;449:719-58.
67. Pugh Jr EN, Lamb TD. Amplification and kinetics of the activation steps in phototransduction. BiochimBiophys Acta. 1993;1141:111-49. (Pubitemid 23070170)
68. Robson JG, Frishman LJ. Response linearity and kinetics of the cat retina: the bipolar cell component of the dark-adapted electroretinogram. Vis Neurosci. 1995;12:837-50.
69. Pugh EN Jr, Falsini B, Lyubarsky AL. The origins of the major rod-and cone-driven components of the rodent electroretinogram and the effect of age and light-rearing history on the magnitude of these components. In: Photostasis and related phenomena. New York: Plenum Press; 1998.
70. Wurziger K, Lichtenberger T, Hanitzsch R. On-bipolar cells and depolarising third-order neurons as the origin of the ERG-b-wave in the RCS rat. Vision Res. 2001;41:1091-101. (Pubitemid 32285382)
71. Wachtmeister L. Some aspects of the oscillatory response of the retina. Prog Brain Res. 2001;131:465-74.
72. Dong CJ, Agey P, Hare WA. Origins of the electroretinogram oscillatory potentials in the rabbit retina. Vis Neurosci. 2004;21:533-43. (Pubitemid 40007266)
73. Akula JD, Mocko JA, Moskowitz A, Hansen RM, Fulton AB. The oscillatory potentials of the dark-adapted electroretinogram in retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2007;48:5788-97. (Pubitemid 351260885)
74. Shirao Y, Kawasaki K. Electrical responses from diabetic retina. Prog Retin Eye Res. 1998;17:59-76. (Pubitemid 28040753)
75. Bresnick GH, Palta M. Oscillatory potential amplitudes. Relation to severity of diabetic retinopathy. Arch Ophthalmol. 1987;105:929-33. (Pubitemid 17092622)
76. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol. 2002;47 Suppl 2:S253-62. (Pubitemid 36351245)
77. Fletcher EL, Phipps JA, Ward MM, Puthussery T, Wilkinson-Berka JL. Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des. 2007;13:2699-712. (Pubitemid 47423662)
78. Kern TS, Barber AJ. Retinal ganglion cells in diabetes. J Physiol. 2008;586:4401-8.
79. Barber AJ, Schuller K, Bridi MA, Bronson SK. Visual acuity and contrast sensitivity are reduced in the Ins2Akita diabetic mouse. ARVO Annual Meeting. 2010.
80. Lecleire-Collet A, Audo I, Aout M, Girmens JF, Sofroni R, Erginay A, Le Gargasson JF, Mohand-Said S, Meas T, Guillausseau PJ, Vicaut E, Paques M, Massin P. Evaluation of retinal function and flicker light-induced retinal vascular response in normotensive patients with diabetes without retinopathy. Invest Ophthalmol Vis Sci. 2011;52:2861-7.
81. van Dijk HW, Kok PH, Garvin M, Sonka M, DeVries JH, Michels RP, van Velthoven ME, Schlingemann RO, Verbraak FD, Abramoff MD. Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50:3404-9.
82. van Dijk HW, Verbraak FD, Kok PH, Garvin MK, Sonka M, Lee K, DeVries JH, Michels RP, van Velthoven ME, Schlingemann RO, Abramoff MD. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Invest Ophthalmol Vis Sci. 2010;51:3660-5.
83. Hayashi Y, Nishio M, Naito Y, Yokokura H, Nimura Y, Hidaka H, Watanabe Y. Regulation of neuronal nitric-oxide synthase by calmodulin kinases. J Biol Chem. 1999;274:20597-602.
84. Rameau GA, Chiu LY, Ziff EB. Bidirectional regulation of neuronal nitric-oxide synthase phosphorylation at serine 847 by the N-methyl-D-aspartate receptor. J Biol Chem. 2004;279:14307-14. (Pubitemid 38468971)
85. Song T, Hatano N, Horii M, Tokumitsu H, Yamaguchi F, Tokuda M, Watanabe Y. Calcium/calmodulin-dependent protein kinase I inhibits neuronal nitric-oxide synthase activity through serine 741 phosphorylation. FEBS Lett. 2004;570:133-7. (Pubitemid 38900970)
86. Song T, Hatano N, Kume K, Sugimoto K, Yamaguchi F, Tokuda M, Watanabe Y. Inhibition of neuronal nitric-oxide synthase by phosphorylation at threonine1296 in NG108-15 neuronal cells. FEBS Lett. 2005;579:5658-62. (Pubitemid 41455645)
87. Chen ZP, McConell GK, Michell BJ, Snow RJ, Canny BJ, Kemp BE. AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation. Am J Physiol Endocrinol Metab. 2000;279:E1202-6.
88. Komeima K, Hayashi Y, Naito Y, Watanabe Y. Inhibition of neuronal nitric-oxide synthase by calcium/ calmodulindependent protein kinase IIalpha through Ser847 phosphorylation in NG108-15 neuronal cells. J Biol Chem. 2000;275:28139-43.
89. Bredt DS, Ferris CD, Snyder SH. Nitric oxide synthase regulatory sites. Phosphorylation by cyclic AMP-dependent protein kinase, protein kinase C, and calcium/calmodulin protein kinase; identification of flavin and calmodulin binding sites. J Biol Chem. 1992;267:10976-81.
90. Rameau GA, Chiu LY, Ziff EB. NMDA receptor regulation of nNOS phosphorylation and induction of neuron death. Neurobiol Aging. 2003;24:1123-33. (Pubitemid 37487890)
91. Kikuchi M, Kashii S, Mandai M, Yasuyoshi H, Honda Y, Kaneda K, Akaike A. Protective effects of FK506 against glutamateinduced neurotoxicity in retinal cell culture. Invest Ophthalmol Vis Sci. 1998;39:1227-32. (Pubitemid 28247358)
92. Dotsch J, Schoof E, Schocklmann HO, Brune B, Knerr I, Repp R, RascherW. Nitric oxide increases adrenomedullin receptor function in rat mesangial cells. Kidney Int. 2002;61:1707-13. (Pubitemid 34437924)
93. Dotsch J, Schoof E, Hanze J, Dittrich K, Opherk P, Dumke K, Rascher W. Nitric oxide stimulates adrenomedullin secretion and gene expression in endothelial cells. Pharmacology. 2002;64:135-9. (Pubitemid 34136854)
94. Ribatti D, Nico B, Spinazzi R, Vacca A, Nussdorfer GG. The role of adrenomedullin in angiogenesis. Peptides. 2005;26:1670-5. (Pubitemid 41169764)
95. Noda K, Ishida S, Inoue M, Obata K, Oguchi Y, Okada Y, Ikeda E. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2003;44:2163-70. (Pubitemid 36520313)
96. Mohammad G, Kowluru RA. Matrix metalloproteinase-2 in the development of diabetic retinopathy andmitochondrial dysfunction. Lab Invest. 2010;90:1365-72.
97. Martinez A, Oh HR, Unsworth EJ, Bregonzio C, Saavedra JM, Stetler-Stevenson WG, Cuttitta F. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J. 2004;383:413-8. (Pubitemid 39546110)
98. Kowluru RA. Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol. 2001;38:179-85. (Pubitemid 34145697)
99. Gardner TW, Antonetti DA. Ruboxistaurin for diabetic retinopathy. Ophthalmology. 2006;113:2135-6. (Pubitemid 44838950)
100. Shiba T, Inoguchi T, Sportsman JR, HeathWF, Bursell S, King GL. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol. 1993;265:E783-93.
101. Araujo IM, Carvalho CM. Role of nitric oxide and calpain activation in neuronal death and survival. Curr Drug Targets CNS Neurol Disord. 2005;4:319-24. (Pubitemid 41086752)
102. Volbracht C, Chua BT, Ng CP, Bahr BA, Hong W, Li P. The critical role of calpain versus caspase activation in excitotoxic injury induced by nitric oxide. J Neurochem. 2005;93:1280-92. (Pubitemid 40776581)